(SLN) Silence Therapeutics plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SLN) Silence Therapeutics plc Complete Analysis Pack
Actionable Strategy Starts Here
This Silence Therapeutics plc BCG Matrix helps you understand how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The page already shows a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to unlock the complete ready-to-use report.
Stars
SLN360, Phase I cardiovascular lead
SLN360 is Silence Therapeutics plc’s most visible standalone clinical asset and its Phase I lead for elevated lipoprotein(a), a risk factor linked to roughly 1 in 5 adults worldwide. That keeps it in the Stars bucket: high market potential, but still early clinical risk. If later-stage data stay strong, it could become the main value driver for Silence Therapeutics plc.
SLN124, Phase I hematology lead
SLN124 is a Phase I hematology lead that targets TMPRSS6, placing Silence Therapeutics plc in rare blood diseases with clear unmet need. Its main shots are non-transfusion-dependent thalassemia and myelodysplastic syndrome, both niche markets where better options can win fast. That makes SLN124 one of Silence Therapeutics plc’s strongest future differentiation bets in a Stars slot.
mRNAi GOLD platform, liver-targeted RNAi engine
mRNAi GOLD is Silence Therapeutics plc’s core discovery engine, built for liver-targeted siRNA design against disease-causing genes. It underpins the pipeline and is the main growth driver because the platform can feed multiple programs from one technology base. In BCG terms, it fits a Star: high strategic value, clear differentiation, and centrality to future pipeline expansion.
AstraZeneca, 4 disease areas
AstraZeneca spans cardiovascular, renal, metabolic and respiratory diseases, four of the biggest and fastest-growing drug markets. Cardiovascular disease caused about 20.5 million deaths in 2021, and chronic kidney disease affects about 10% of adults worldwide, so the addressable pool is huge. For Silence Therapeutics, this deal adds reach and scale beyond its internal pipeline.
- Large, durable demand
- Multi-disease commercial scale
- Stronger partner-led reach
RNAi platform, 2 clinical-stage assets
Silence Therapeutics plc’s RNAi platform was backed by 2 named clinical programs by end-2025, giving the company a concentrated but high-upside pipeline. That matters because the lead assets drive most near-term value in biotech, while the platform can still spawn follow-on shots. In 2025, Silence reported cash, cash equivalents and short-term investments of about $202.9 million, supporting these programs.
- 2 named clinical programs by end-2025
- High-conviction, focused pipeline
- $202.9 million cash and equivalents in 2025
Silence Therapeutics’ Cash, Pipeline, and Platform Power Growth
Silence Therapeutics plc’s Stars are its two clinical leads and platform engine: SLN360, SLN124, and mRNAi GOLD. In 2025, the company held about $202.9 million in cash, cash equivalents and short-term investments, which helps fund these high-upside programs. AstraZeneca also broadens reach into large, fast-growing disease areas.
| Star | Why it matters |
|---|---|
| SLN360 | Phase I, Lp(a) |
| SLN124 | Phase I, rare blood disease |
| mRNAi GOLD | Core RNAi platform |
What is included in the product
Detailed Word Document
BCG Matrix for Silence Therapeutics plc: identify Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Clear BCG Matrix snapshot of Silence Therapeutics plc to quickly spot growth, cash, and drag areas.
Reference Sources
Provides a credible source trail for Silence Therapeutics plc, helping users verify key claims quickly and make better decisions.
Cash Cows
AstraZeneca collaboration, milestone cash
AstraZeneca collaboration cash is a core Cash Cow for Silence Therapeutics plc because it can deliver upfront payments, milestones, and funded development work without issuing new shares. That makes it non-dilutive cash, unlike pure internal R&D spend. In BCG terms, it is one of the clearest recurring funding engines in the business.
Hansoh collaboration, 3 targets
Hansoh gives Silence Therapeutics plc 3 siRNA targets, so the platform keeps turning discovery into cash. The pact can shift part of the R&D bill to Hansoh and add milestone income later; deals of this type can reach up to US$1.8 billion in aggregate value, plus royalties. That makes it a clean monetization channel for the RNAi platform.
Mallinckrodt partnership, complement disorders
Silence Therapeutics plc’s Mallinckrodt partnership targets complement cascade genes, giving the company a partnered route in complement-mediated disorders. This matters because such deals can convert research into shared commercialization cash flow, while Mallinckrodt funds much of the late-stage burden. That lowers Silence Therapeutics plc’s capital drag and keeps program risk off its own balance sheet.
Partner-funded R&D, non-dilutive model
Silence Therapeutics plc uses partner-funded R&D to reduce its own cash burn, so collaboration income can offset discovery and early development spend. For a pre-revenue biotech, that makes this the closest thing to a cash cow: in FY2025, the model kept dilution lower than fully self-funded pipelines while preserving pipeline access and shared risk.
- Partners help fund R&D spend
- Lower direct cash burn
- Less dilution than pure equity funding
- Best-fit cash engine for pre-revenue biotech
Platform licensing, recurring monetization
Silence Therapeutics plc’s platform licensing is the mature Cash Cow in its BCG mix: one siRNA platform can be out-licensed across liver and other disease areas, so revenue comes from repeat deals, upfront fees, milestones, and royalties rather than one-shot discovery wins. That makes monetization steadier and less binary, even if 2025/2026 company filings still show the core value is in future partner-led deal flow, not product sales.
- Multi-asset out-licensing lowers single-program risk.
- Recurring deal terms improve cash visibility.
- Best fit for stable, mature monetization.
Silence Therapeutics’ Cash Cow Deals Cut Burn and Dilution
Silence Therapeutics plc’s Cash Cows are partner-funded deals that turn its siRNA platform into recurring upfront fees, milestones, and shared R&D cash. In FY2025, this model helped offset burn and reduced dilution versus fully self-funded programs. Hansoh can cover up to US$1.8 billion in deal value, while AstraZeneca and Mallinckrodt keep cash flow tied to active programs.
| Cash Cow | Value |
|---|---|
| Hansoh | Up to US$1.8bn |
| Funding model | Lower burn |
| FY2025 impact | Less dilution |
Get Your Copy
Silence Therapeutics plc Reference Sources
The Silence Therapeutics plc BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No sample pages, no watermarks, and no hidden changes—just the full, ready-to-use report. Once purchased, you’ll get immediate access to the final file for download, editing, or presentation.
Dogs
0 approved medicines
Silence Therapeutics plc ended 2025 with 0 approved medicines, so it had no marketed product to defend share in a mature market. That leaves no cash-generating asset to offset R&D burn or fund scale from sales. In BCG terms, this is a pure Dogs position: low market presence and no commercial moat yet.
0 marketed brands
Silence Therapeutics plc has 0 marketed brands, so it has no pharmacy or hospital sales to defend. That means its commercial footprint is still zero and there is no installed customer base, recurring product revenue, or brand-led share to protect. In 2025, this leaves the Dogs bucket driven by pipeline value only, not by any sold product base.
0 product sales
In 2025, Silence Therapeutics plc reported £0 product sales, so revenue was not driven by commercial product demand but by collaboration income. That means the business has no sales-backed operating engine yet, which is a classic Dogs sign in the BCG Matrix. With no product revenue base, market share remains low and scaling risk stays high.
0 mature royalty streams
Silence Therapeutics plc has 0 mature royalty streams, so it gets no meaningful sales-based cash inflow today. With no approved launch, royalty income is still nil, and the company remains reliant on funding rounds and deal partners. That also limits self-funding; at 2025 year-end, the key question is burn, not royalties.
- 0 approved launches
- No royalty cash flow
- Depends on financing
- Weak self-funding
Legacy commercial footprint absent
Silence Therapeutics plc is still research-led, not commercial-led: it has no approved product sales, no mature field sales force, and no proven launch or promotion engine. In BCG terms, this is not a low-growth cash cow with durable share; it is pre-commercial and depends on R&D execution.
Latest filings still point to a company funded by pipeline progress, not market share, so the Dogs bucket does not fit a legacy business footprint. That matters because without distribution scale, there is no stable revenue base to defend.
- No approved product sales
- No mature launch network
- No durable commercial share
Silence Therapeutics Remains a Pure R&D Story, Not a Commercial One
Silence Therapeutics plc fits Dogs in the BCG Matrix because it ended 2025 with £0 product sales, 0 approved launches, and 0 royalty cash flow. With no marketed brands or mature sales engine, it had no defendable market share or self-funding cash base. Its 2025 position stayed research-led, not commercial-led.
| Metric | 2025 |
|---|---|
| Approved launches | 0 |
| Product sales | £0 |
| Royalty cash flow | 0 |
| Marketed brands | 0 |
Question Marks
SLN360, Phase I lipoprotein(a) risk
SLN360 is still a Question Mark: in Phase 1, a single dose cut lipoprotein(a) by up to 98% over 150 days, but it has no outcomes data yet and clinical success is still unproven. Lp(a) is a huge market if it works, with about 20% of people worldwide carrying elevated levels, but Silence Therapeutics plc has not shown clear commercial fit. More data is needed, or the program can stall.
SLN124, Phase I non-transfusion-dependent thalassemia
SLN124 in non-transfusion-dependent thalassemia is still in Phase I, so the data are too early to call it a Star or Cash Cow. Thalassemia is a serious rare-disease market, but uptake will hinge on clear safety and durable hemoglobin gains, especially if patients can avoid regular transfusions. For now, this looks like a classic invest-or-wait case for Silence Therapeutics plc.
SLN124, Phase I myelodysplastic syndrome
SLN124 is still in Phase I for myelodysplastic syndrome, so it has only early human data and no proven commercial traction yet. MDS is a high-unmet-need blood cancer setting, but Silence Therapeutics has not shown late-stage efficacy or approval, which keeps the asset in question-mark territory. The key test is whether early safety and target engagement can turn into durable response rates in a patient group where current options remain limited.
SLN124, planned polycythemia vera
SLN124’s planned polycythemia vera program still sits in the Question Marks bucket: the asset has upside, but it is not yet de-risked by late-stage clinical data. Polycythemia vera is a rare hematology market, so a clean efficacy and safety signal could make it meaningful for Silence Therapeutics plc; until then, it remains a capital-consuming option.
Upside depends on phase data.
Risk remains high today.
Cash burn is likely to continue.
Mallinckrodt complement program, early development
Mallinckrodt’s complement-cascade program is still an early-stage bet, so it fits the Question Mark slot in Silence Therapeutics plc’s BCG matrix. At end-2025, there is no late-stage clinical proof yet, so the value case still rests on whether target biology and human data line up. One clean read: high upside, low evidence.
- Early stage
- No late-stage proof
- High optionality
- Still more promise than proof
Early Promise, Still High Risk: Silence’s Catalysts Aren’t De-Risked Yet
Silence Therapeutics plc’s Question Marks are still all about future readouts, not proven sales: SLN360 cut lipoprotein(a) by up to 98% after one dose, but it is still Phase 1 and has no outcomes data. SLN124 in NTDT, MDS, and planned PV also remains early-stage, so upside is real but not de-risked.
| Asset | Stage | Key signal |
|---|---|---|
| SLN360 | Phase 1 | Up to 98% Lp(a) drop |
| SLN124 | Phase 1 | Early human data only |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.